Skip to main content

Metformin use is associated with better survival of diabetic patients with pancreatic cancer.

Publication ,  Journal Article
Sadeghi, N; Abbruzzese, JL; Yeung, S-CJ; Hassan, M; Li, D
Published in: Clin Cancer Res
May 15, 2012

PURPOSE: Accumulating evidence suggests that metformin has antitumor activity. The aim of this study was to determine whether metformin use has a survival benefit in patients with pancreatic cancer. EXPERIMENTAL DESIGN: We conducted a retrospective study of patients with diabetes and pancreatic cancer treated at The University of Texas MD Anderson Cancer Center (Houston, TX). Information on diabetes history, including treatment modalities and clinical outcome of pancreatic cancer, was collected using personal interviews and medical record review. Survival analysis was carried out using a Kaplan-Meier plot, log-rank test, and Cox proportional hazards regression models. RESULTS: Among the 302 patients identified, there were no significant differences in demographic or major clinical characteristics between the patients who had received metformin (n = 117) and those who had not (n = 185). The 2-year survival rate was 30.1% for the metformin group and 15.4% for the non-metformin group (P = 0.004; χ(2) test). The median overall survival time was 15.2 months for the metformin group, and 11.1 months for the non-metformin group (P = 0.004, log-rank test). Metformin users had a 32% lower risk of death; the HR (95% confidence interval) was 0.68 (0.52-0.89) in a univariate model (P = 0.004), 0.64 (0.48-0.86) after adjusting for other clinical predictors (P = 0.003), and 0.62 (0.44-0.87) after excluding insulin users (P = 0.006). Metformin use was significantly associated with longer survival in patients with nonmetastatic disease only. CONCLUSIONS: Our finding that metformin use was associated with improved outcome of patients with diabetes and pancreatic cancer should be confirmed in independent studies. Future research should prospectively evaluate metformin as a supplemental therapy in this population.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Clin Cancer Res

DOI

EISSN

1557-3265

Publication Date

May 15, 2012

Volume

18

Issue

10

Start / End Page

2905 / 2912

Location

United States

Related Subject Headings

  • Retrospective Studies
  • Pancreatic Neoplasms
  • Oncology & Carcinogenesis
  • Middle Aged
  • Metformin
  • Male
  • Kaplan-Meier Estimate
  • Hypoglycemic Agents
  • Humans
  • Female
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Sadeghi, N., Abbruzzese, J. L., Yeung, S.-C., Hassan, M., & Li, D. (2012). Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clin Cancer Res, 18(10), 2905–2912. https://doi.org/10.1158/1078-0432.CCR-11-2994
Sadeghi, Navid, James L. Abbruzzese, Sai-Ching J. Yeung, Manal Hassan, and Donghui Li. “Metformin use is associated with better survival of diabetic patients with pancreatic cancer.Clin Cancer Res 18, no. 10 (May 15, 2012): 2905–12. https://doi.org/10.1158/1078-0432.CCR-11-2994.
Sadeghi N, Abbruzzese JL, Yeung S-CJ, Hassan M, Li D. Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clin Cancer Res. 2012 May 15;18(10):2905–12.
Sadeghi, Navid, et al. “Metformin use is associated with better survival of diabetic patients with pancreatic cancer.Clin Cancer Res, vol. 18, no. 10, May 2012, pp. 2905–12. Pubmed, doi:10.1158/1078-0432.CCR-11-2994.
Sadeghi N, Abbruzzese JL, Yeung S-CJ, Hassan M, Li D. Metformin use is associated with better survival of diabetic patients with pancreatic cancer. Clin Cancer Res. 2012 May 15;18(10):2905–2912.

Published In

Clin Cancer Res

DOI

EISSN

1557-3265

Publication Date

May 15, 2012

Volume

18

Issue

10

Start / End Page

2905 / 2912

Location

United States

Related Subject Headings

  • Retrospective Studies
  • Pancreatic Neoplasms
  • Oncology & Carcinogenesis
  • Middle Aged
  • Metformin
  • Male
  • Kaplan-Meier Estimate
  • Hypoglycemic Agents
  • Humans
  • Female